A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the
Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single
subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with
Hereditary Angioedema (HAE) during an initial acute attack.